A5071900951- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Cancer, Lipids, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Treatments and Mutations
- Ethics in Clinical Research
- Health Systems, Economic Evaluations, Quality of Life
- Colorectal Cancer Surgical Treatments
- Neuroendocrine Tumor Research Advances
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Screening and Detection
- Cancer survivorship and care
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Palliative Care and End-of-Life Issues
- Patient-Provider Communication in Healthcare
- Colorectal and Anal Carcinomas
- ECG Monitoring and Analysis
- COVID-19 Clinical Research Studies
- Gestational Trophoblastic Disease Studies
- Multiple and Secondary Primary Cancers
- Genetic factors in colorectal cancer
- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Pancreatitis Pathology and Treatment
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2014-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2024
Ospedale Infermi di Rimini
2006
University of Leicester
1954
INTRODUCTION: Pancreatic cancer (PC) surveillance of high-risk individuals (HRI) is becoming more common worldwide, aiming at anticipating PC diagnosis a preclinical stage. In 2015, the Italian Registry Families Risk Cancer was created. We aimed to assess prevalence and incidence pancreatic findings, oncological outcomes, harms 7 years after inception, focusing on with least 3-year follow-up or developing events before. METHODS: HRI (subjects family history mutation carriers with/without...
Neuroendocrine Carcinomas (NECs) prognosis is poor.No standard second-line therapy currently recognized after failure of platinum-based first-line treatment. FOLFIRI and CAPTEM regimens have shown promising activity in preliminary studies. We aimed to evaluate these metastatic NEC patients.
Abstract Preliminary studies suggest that capecitabine may be safe and effective in HCC patients. The aim of this study was to retrospectively evaluate the safety efficacy metronomic as second-line treatment. This multicentric analyzed data patients unresponsive or intolerant sorafenib treatment with best supportive care (BSC).Median progression free survival 3.1 months treated (95%CI: 2.7–3.5). Median overall 12.0 (95% CI: 10.7–15.8) receiving capecitabine, while 9.0 6.5–13.9) BSC. result...
The assessment of inoperability bronchial carcinoma by angiocardiography has received little attention in this country, and it is the purpose paper to discuss value investigation analysing our results 31 cases at Leicester Chest Unit.Since introduction Robb Steinberg 1938 many authors have described its use differential diagnosis lesions lungs mediastinum, but not intended aspect.The possibility assessing operability neoplasm was first suggested Steinberg, Dotter, Andrus (1950).Dotter 1952...
Lipoplatin™ is a liposome encapsulated form of cisplatin. Phase I studies on lipoplatin have demonstrated that the compound has an excellent toxicity profile. Therefore we performed phase II trial in heavily pre-treated patients with advanced non-small-cell lung cancer (NSClC), performance status 0-2 which primary end-point was response rate and secondary endpoints were safety overall survival.Nineteen patients, average age 64 years old, stage IV NSClC, treated 100 mg/m2 every two weeks, as...
Abstract Purpose: After 10 years of clinical practice and research studies, there are still no validated prognostic or predictive factors response to sorafenib for hepatocellular carcinoma (HCC). On the basis results our two retrospective we designed multicenter INNOVATE study with aim validate role nitric oxide synthase 3 (NOS3) ANGPT2 polymorphisms in patients HCC treated [NCT02786342]. Patients Methods: This prospective was conducted at centers Italy. All eligible received a continuous...
PURPOSE: Cancer clinical trials (CTs) are now more complex than ever before and require dedicated personnel (clinical research coordinators [CRCs]) to perform regulatory administrative activities protocol- patient-related procedures. We developed a simple tool measure the workload (WL) of CRCs involved in cancer estimate requirements within Clinical Trial Center. METHODS: A literature review 2-month period which recorded their diary provided valuable information that led Istituto Scientifico...
Patients' awareness of clinical research and their involvement in trials is great importance, but it difficult to estimate the extent knowledge on being undertaken.We evaluated level about using a self-reporting survey distributed 967 adult patients with cancer attending Departments Medical Oncology Onco-Haematology Units IRST IRCCS 4 hospitals region Emilia-Romagna, Italy. The questionnaire was composed 10 specific items knowledge. Patients responding correctly at least 8 were considered...
Aims: This study aims to evaluate the safety and efficacy of a new neoadjuvant regimen (FOLFOX4 plus hypofractionated tomotherapy) in patients with locally advanced rectal cancer. Methods: Patients stage II–III cancer were treated pre-operative chemoradiotherapy comprising FOLFOX4 (two cycles), TomoTherapy (25 Gy five consecutive fractions, one fraction per day 5 days on clinical target volume at isodose 95% total dose), followed by surgery mesorectal excision adjuvant chemotherapy (eight...
<p>All Supplementary Data</p>
<p>All Supplementary Data</p>
<div>AbstractPurpose:<p>After 10 years of clinical practice and research studies, there are still no validated prognostic or predictive factors response to sorafenib for hepatocellular carcinoma (HCC). On the basis results our two retrospective we designed multicenter INNOVATE study with aim validate role nitric oxide synthase <i>3</i> (<i>NOS3</i>) <i>ANGPT2</i> polymorphisms in patients HCC treated [NCT02786342].</p>Patients...